Novo Nordisk A/S (NVO) - Stock Price & Dividends

Exchange: USA Stocks • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US6701002056

Insulin, Diabetes, Obesity, Hormone, Rare Disease treatments

Novo Nordisk A/S is a global healthcare company that develops, manufactures, and distributes a wide range of pharmaceutical products to improve the lives of people worldwide. With a presence in Europe, the Middle East, Africa, Asia, and the Americas, the company is committed to making a difference in the lives of millions of people.

The company operates through two main business segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment focuses on developing innovative treatments for diabetes, obesity, and related cardiovascular diseases, as well as emerging therapy areas. This segment is dedicated to improving the lives of people living with diabetes and obesity, and to reducing the burden of these diseases on individuals, families, and societies.

The Rare Disease segment, on the other hand, specializes in developing life-changing treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. This segment is committed to making a meaningful difference in the lives of people affected by these rare and often debilitating conditions.

Novo Nordisk A/S is also a leader in innovative delivery systems, offering a range of products such as insulin pens, growth hormone pens, and injection needles that make it easier for people to manage their conditions. The company's smart solutions, including smart insulin pens and the Dose Check insulin dose guidance application, are designed to simplify diabetes treatment and improve health outcomes.

In addition to its internal research and development efforts, Novo Nordisk A/S collaborates with other companies, such as Aspen Pharmaceuticals, to produce insulin products that meet the highest standards of quality and efficacy. With a rich history dating back to 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark, and is committed to continuing its legacy of innovation and excellence in the years to come.

For more information about Novo Nordisk A/S and its products, please visit

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Novo Nordisk A/S (NVO) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Novo Nordisk A/S (NVO) - Stock Price & Dividends

NVO Stock Overview

Market Cap in USD 634,288m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1982-01-04

NVO Stock Ratings

Growth 5y 96.4
Fundamental 79.7
Dividend 7.21
Rel. Performance vs Sector 4.59
Analysts 4.18/5
Fair Price Momentum 184.89 USD
Fair Price DCF 309.54 USD

NVO Dividends

Yield 12m 0.69%
Yield on Cost 5y 4.04%
Dividends CAGR 5y 10.95%
Payout Consistency 80.0%

NVO Growth Ratios

Growth 12m 80.01%
Growth Correlation 12m 84%
Growth Correlation 3m 58%
CAGR 5y 42.39%
CAGR/Mean DD 5y 8.83
Sharpe Ratio 12m 2.34
Alpha vs SP500 12m 58.89
Beta vs SP500 5y weekly 0.72
ValueRay RSI 56.71
Volatility GJR Garch 1y 27.37%
Price / SMA 50 7.22%
Price / SMA 200 24.83%
Current Volume 3023k
Average Volume 20d 3501.3k

External Links for NVO Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of NVO stocks?
As of June 22, 2024, the stock is trading at USD 141.96 with a total of 3,022,965 shares traded.
Over the past week, the price has changed by -0.38%, over one month by +5.03%, over three months by +9.90% and over the past year by +78.36%.
What are the forecast for NVO stock price target?
According to ValueRays Forecast Model, NVO Novo Nordisk A/S will be worth about 204.6 in June 2025. The stock is currently trading at 141.96. This means that the stock has a potential upside of +44.14%.
Issuer Forecast Upside
Wallstreet Target Price 151.2 6.49
Analysts Target Price 80.4 -43.4
ValueRay Target Price 204.6 44.1

Understanding Novo Nordisk: From Origins to Modern Market

History of Novo Nordisk

Novo Nordisk has its origins in early 20th-century Denmark, with its foundation deeply rooted in the discovery and development of insulin. Established from the merger of two Danish companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium in 1989, it has a legacy of innovation and dedication towards diabetes care. This merger was not just a merging of names but of decades of research, commitment, and a shared mission to defeat diabetes and other serious chronic conditions.

Core Business

At the heart of Novo Nordisk's operations is the commitment to be a driving force in diabetes care. The company leads the market in diabetes treatments, providing a wide range of products including insulin, GLP-1 receptor agonists, and treatments for obesity. Diabetes care, however, is only part of the picture. The company is also invested in haemophilia treatments, growth hormone therapy, and hormone replacement therapy – addressing a wider spectrum of chronic diseases and conditions.

Side Business and Extensions

Beyond its primary focus, Novo Nordisk has ventured into areas such as obesity management, offering innovative solutions and treatments. This includes weight management products that complement its diabetes care portfolio, underscoring its holistic approach to tackling complex health problems. Moreover, the company has a growing presence in the biopharmaceutical sector, exploring treatments in new therapeutic areas, reflecting its ongoing commitment to push the boundaries of healthcare and improve patient outcomes.

Current Market Status

As of the current market landscape, Novo Nordisk A/S (NYSE:NVO) enjoys a robust position. Supported by a strong product pipeline and a steadfast focus on research and development, it continues to grow its global market share. The company's financial health remains solid, demonstrating resilience and adaptability even in the face of economic fluctuations and changing healthcare environments. With a clear strategic direction and dedication to innovation, Novo Nordisk is well-equipped to navigate future challenges and opportunities in the healthcare sector.